ComplyRx
Built by ComplyRx

Compare clinical trial pipelines, export for presentations

deucravacitinib (16) vs dupilumab (16)21 active2014–2032
deucravacitinibdupilumab
Key
Actual date
Anticipated
Forecast to primary completion
RecruitingActive, not recruitingNot yet recruitingCompletedTerminated
'14
'16
'18
'20
'22
'24
'26
'28
'30
'32
deucravacitinib
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus ErythematosusP2
An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's DiseaseP2
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus ErythematosusP2
Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative ColitisP2
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)P2
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic DrugsP3
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor TreatmentP3
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia AreataP2
POETYK SLE-1P3
POETYK SLE-2P3
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital PsoriasisP4
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)P3
ViTYKP2
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque PsoriasisP3
COMBoP4
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study CompletersP3
dupilumab
Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)P2
SOLO 2P3
SOLO-CONTINUEP3
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)P3
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)P3
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)P3
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)P3
LIBERTY-BPP2
GENESISP2
ATLASP4
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)P3
DUPLEX-ADP2
AEOLUSP4
WIDUSAP4
A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic DermatitisP2
MISSIONP4

Upcoming readouts

12 ahead · 2 drugs

Select a trial to load its full ClinicalTrials.gov record.

Trial Pipeline · How it works

Search, compare, export.

Three steps from drug name to a presentation-ready pipeline view, with live trial data, side by side.

  1. 01 · SEARCH

    Search drugs

    Type a drug name and see the phase 2-4 trials from ClinicalTrials.gov.

  2. 02 · COMPARE

    Compare timelines

    See start dates, primary completions, and status on one timeline, up to five drugs at once.

  3. 03 · EXPORT

    Export for your deck

    Download a branded PNG or PDF. Share the URL. Every comparison state is linkable.

FAQ

Where does the data come from?
All trial data is sourced from ClinicalTrials.gov (CTGov). Results are cached for up to 6 hours so repeat loads stay fast.
Is this free?
Yes. Compare up to five drugs and export PNG or PDF at no cost. Export requires a one-time email to join the ComplyRx waitlist.
What is ComplyRx?
ComplyRx is an all-in-one marketing/competitive intelligence platform for organisations and individuals that work in healthcare, life sciences, and the pharmaceutical industry.

Keep following
what matters.

Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

Build your watch

Choose what to track in the watch builder.